Aclaris (ACRS) witnessed a jump in share price last session on above-average trading volume. The lat

Gainers Alzamend Neuro (NASDAQ:ALZN) stock increased by 12.9% to $1.35 during Tuesday's after-m

Investing in penny stocks requires significant conviction. Many of the companies in this group are p

U.S. stock futures mixed. SL Science shares fall 11.4% after reporting financial results. Other stoc

Investing in penny stocks requires significant conviction. Many of the companies in this group are p

Aclaris Therapeutics NASDAQ: ACRS executives outlined a busy clinical calendar for the biotechnology

Top Wall Street analysts begin coverage of Aclaris Therapeutics, Orion Group Holdings, and Take-Two

WAYNE, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-s

Aclaris Therapeutics, Inc. (ACRS) Presents at Bank of America Global Healthcare Conference 2026 Tran

WAYNE, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-s

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.15 per share versus the Zacks Conse

Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.15) per share which met the anal

- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Exceed Aclaris' Target Profile, Valid

Piper Sandler analyst Biren Amin maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight a

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Cit

Guggenheim analyst Seamus Fernandez initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with

Wedbush analyst Martin Fan maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and ra

Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific

"These results validate that ATI-052 is a highly potent and well tolerated bispecific antibody t

- Positive Full Results from Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Exceed A

Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on deve

WAYNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical

Oppenheimer analyst Jeff Jones initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Ou

Aclaris Therapeutics, Inc. (NASDAQ: ACRS - Get Free Report) saw a significant increase in short inte

WAYNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical

Wedbush analyst Martin Fan reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Outperform and m

- Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Me

- Participants with Atopic Dermatitis Receiving ATI-2138 Experienced Improvements in Key Clinical Me

Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on deve

WAYNE, Pa., March 20, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS)

- Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWI

Aclaris Therapeutics (NASDAQ: ACRS) outlined multiple clinical and near-term development milestones

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.16 per share versus the Zacks Conse

Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.16) per share which missed the a

- Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-

    Thursday morning saw 168 companies set new 52-week highs.

  During Wednesday's morning trading, 254 companies set new 52-week highs.

Stocks That Hit 52-Week Lows On Thursday

Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 19, 2018

Stocks Which Set New 52-Week Low Yesterday, October 9th

Stocks Which Set New 52-Week Low Friday, October 5th